LADA and MODY Difference acc to harrison 22nd edition
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
I have comprehensive Harrison's 22nd edition content on both LADA and MODY. Now I can compile the full detailed answer.
Here is a comprehensive comparison of LADA and MODY as described in Harrison's Principles of Internal Medicine, 22nd Edition (2025).
LADA vs MODY - Harrison's 22nd Edition
LADA (Latent Autoimmune Diabetes in Adults)
Harrison's describes LADA in the context of Type 1 DM classification, noting that it represents a slowly progressive, adult-onset form of immune-mediated diabetes.
Key Features (per Harrison's 22E):
| Feature | Details |
|---|---|
| Pathogenesis | Immune-mediated, autoimmune destruction of pancreatic beta cells (same mechanism as classic T1DM) |
| Age of onset | Adults (older than classic T1DM) |
| Onset speed | Indolent, slowly progressive - not the rapid onset seen in childhood T1DM |
| Beta cell loss | Gradual, with a lengthy prodromal phase |
| Autoantibodies | Positive for islet autoantibodies (GAD65, IA-2, ZnT8, etc.) |
| Initial presentation | May initially appear like T2DM; may respond transiently to non-insulin therapy |
| Insulin requirement | Progresses to insulin dependence, but more slowly than classic T1DM |
| Insulin secretion | Preserved initially due to slower autoimmune destruction |
| C-peptide | Detectable initially, progressively declines |
| Epigenetic mechanism | Hypermethylation of the FOXP3 gene (which activates regulatory T cells) has been noted in LADA patients |
Harrison's states: "Whereas infants and children tend to demonstrate rapid beta-cell death, adults typically present with a lengthy prodromal phase leading to latent autoimmune diabetes of adulthood (LADA)."
MODY (Maturity-Onset Diabetes of the Young) / Monogenic Diabetes
Harrison's 22E uses the term "Monogenic Diabetes" as the preferred descriptor, with MODY as an older alternative name. It is classified under "Other specific types of DM" (Category III in Table 415-1).
Key Features (per Harrison's 22E):
| Feature | Details |
|---|---|
| Pathogenesis | Single-gene mutations - NOT autoimmune. Mutations in genes encoding islet-enriched transcription factors, glucokinase, insulin, and other islet factors |
| Inheritance | Autosomal dominant |
| Age of onset | Usually <25 years (sometimes neonatal period) |
| Primary defect | Impaired insulin secretion (not immune destruction, not primarily insulin resistance) |
| Autoantibodies | Negative |
MODY Subtypes per Harrison's 22E (Table 415-1 & text):
| Type | Gene | Chromosome | Key Features |
|---|---|---|---|
| MODY 1 | HNF-4α (hepatocyte nuclear factor 4α) | 20q13.12 | AD inheritance |
| MODY 2 | Glucokinase | - | Mild-to-moderate stable hyperglycemia; typically does not require pharmacotherapy |
| MODY 3 | HNF-1α | - | Progressive glycemic decline; responds well to sulfonylureas (some initially misdiagnosed as T1DM) |
| MODY (HNF-1β) | HNF-1β | - | Progressive insulin secretion impairment; hepatic insulin resistance; requires insulin; associated with renal cysts, mild pancreatic exocrine insufficiency, abnormal LFTs |
| Others | Insulin promoter factor-1, NeuroD1, KLF11, PAX4, BLK, GATA4, GATA6, SLC2A2 (GLUT2), GLIS3 | - | Various |
Harrison's states: "Monogenic diabetes, sometimes referred to as MODY, are caused by mutations in genes encoding islet-enriched transcription factors, glucokinase, insulin, and other islet factors and present with an autosomal dominant mode of transmission."
A clinical pearl from Harrison's: "Individuals with an HNF-1α mutation (MODY 3) have a progressive decline in glycemic control but may respond to sulfonylureas. In fact, some of these patients were initially thought to have type 1 DM but were later shown to respond to a sulfonylurea, and insulin was discontinued."
Head-to-Head Comparison Table
| Parameter | LADA | MODY (Monogenic DM) |
|---|---|---|
| Classification | Subtype of Type 1 DM | Separate "Other specific type" (Category III) |
| Pathogenesis | Autoimmune beta cell destruction | Single-gene mutation impairing insulin secretion |
| Inheritance | Not typically hereditary (polygenic susceptibility) | Autosomal dominant |
| Age of onset | Adults | Usually <25 years (can be neonatal) |
| Onset speed | Slow, indolent | Variable by subtype |
| Autoantibodies | Positive (GAD65, IA-2, ZnT8) | Negative |
| Insulin resistance | Not a primary feature | Not a primary feature |
| Primary defect | Immune-mediated beta cell destruction | Impaired insulin secretion from gene mutation |
| C-peptide | Declines over time | Present (secretory defect, not destruction) |
| BMI | Variable | Typically normal/lean |
| Treatment | Progresses to insulin | Varies: MODY 2 - diet/lifestyle; MODY 3 - sulfonylurea; HNF-1β - insulin |
| Genetic testing | Not required | Required for definitive diagnosis |
| Family history | Not a defining feature | Strong (AD pattern - 50% risk in offspring) |
Atypical Diabetes (mentioned in same section)
Harrison's also describes "Atypical Diabetes" at line 521 - these are distinct from MODY as they have not been linked to single-gene defects, and include presentations such as:
- T2DM phenotype before puberty
- T2DM phenotype in very lean individuals
- T1DM phenotype with variable autoantibody positivity
Source: Harrison's Principles of Internal Medicine, 22nd Edition (2025) - Chapter 415, pp. 3239-3246
This is a shared conversation. Sign in to Orris to start your own chat.